WEAK BUY
Book value is about $8 a share. Drug companies always seem to do well.
DON'T BUY
He's done poorly in steels over the years. Could drop further.
DON'T BUY
He's done poorly in steels over the years. Could be in for a tough haul.
PAST TOP PICK
(Was a top pick on Apr 24/03. Down 2%.) Still likes. Recently had a bad quarter. Moving more and more into the states which is good. Good management.
PAST TOP PICK
(Was a top pick on Apr 24/03. Up 5%.) Still likes. Tremendous assets. Very focused. Large debt load.
PAST TOP PICK
(Was a top pick on Apr 24/03. Up 18%.) Still likes. Clean balance sheet. No long term debt.
DON'T BUY
On their watch list. Since they first came out, revenues has dropped and debt has risen. Still in a major danger zone.
BUY
It has potential and might be worth a small play.
DON'T BUY
On their watch list. Debt load scares them. Not enough margin of safety.
DON'T BUY
Not watching them because it hasn't dropped far enough yet.
WEAK BUY
Could be worthwhile if you feel bank mergers will occur.
WAIT
On their watch list. Will look at it closer later in the year.
DON'T BUY
Have to be careful in dealing with "discoveries". High risk.
DON'T BUY
New CEO is good, buty doesn't watch companies less than 10 years old.
DON'T BUY
They need the preice of gold to be $350 and ounce in order to break even. Continues to lose money.